In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode cVDPV2 detections in Burundi and the DRC (PGEI) Novel oral polio vaccine type 2 story (The Lancet) Prior COVID-19 infection associated with risk of diagnosed erectile dysfunction (IJIR) Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection (BMJ)  Protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals(The Lancet) Effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths (The Lancet) Projected COVID-19 mortality reduction from Paxlovid rollout (JAMA) SARS-CoV-2 mRNA vaccines decouple anti-viral immunity (Nature)  Contribute to our ASTMH fundraiser at PWB Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 994 Don’t crush Paxlovid (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• cVDPV2 detections in Burundi and the DRC (PGEI)
• Novel oral polio vaccine type 2 story (The Lancet)
• Prior COVID-19 infection associated with risk of diagnosed erectile dysfunction (IJIR)
• Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection (BMJ) 
• Protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals(The Lancet)
• Effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths (The Lancet)
• Projected COVID-19 mortality reduction from Paxlovid rollout (JAMA)
• SARS-CoV-2 mRNA vaccines decouple anti-viral immunity (Nature) 
• Contribute to our ASTMH fundraiser at PWB
• Dr. Griffin’s treatment guide (23-2023.pdf">pdf)
• Letters read on TWiV 994
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv